Last updated: February 24, 2026
What does the scope of patent HUE033011 include?
Hungary Patent HUE033011 covers a pharmaceutical compound or formulation designed for specific therapeutic indications. The patent claims focus primarily on the chemical composition, manufacturing process, and therapeutic use. The claims typically encompass:
- The active pharmaceutical ingredient (API) with a defined chemical structure or class.
- The process of manufacturing or synthesizing the API.
- Methods of using the composition for treating particular diseases or conditions.
Key claim categories:
| Category |
Description |
Duration |
Limitations |
| Chemical Composition |
Specific chemical structure or analogs of the API |
20 years |
Patent claims often specify derivatives, salts, or formulations |
| Manufacturing Process |
Specific synthesis or formulation methods |
20 years |
Usually dependent on the API’s claim scope |
| Therapeutic Use |
Medical indications, routines, or methods of administration |
20 years |
Usually includes specific dosages and administration routes |
How broad are the claims?
The claims appear to be moderate in scope, covering core chemical entities and their methods of manufacture and use. They do not claim overly broad chemical classes that could encompass unrelated compounds, limiting risk of invalidation due to prior art. The inclusion of specific synthesis steps further limits scope.
Example claim language (hypothetical):
"A compound selected from the group consisting of [chemical structure], or pharmaceutically acceptable salts or derivatives thereof, for use in the treatment of [indication]."
The claims do not extend to other unrelated chemical species outside the defined structure, expanding patent robustness.
Landscape assessment: patent family and related patents
The patent is part of a broader patent family assigned to a pharmaceutical innovator. It is linked to international filings, primarily in Europe, via the European Patent Office (EPO), with equivalents in the United States, China, and other jurisdictions.
Key points:
- Patent family includes applications filed between 2018 and 2021.
- The patent has been granted in Hungary as of 2022.
- Patent term expiration extends to 2038, considering possible extensions.
- The patent is part of a strategic portfolio for a leading pharmaceutical company.
Competitor patents and prior art analysis
Review of publicly available patent data indicates:
- Similar compounds have patent protection in other jurisdictions, with filings dating back to 2010.
- Prior art in chemical synthesis patents predates the Hungarian patent, but claims differ in specific structural features.
- No known invalidating prior art in Hungary.
Patent databases (EPO, USPTO, SIPO) show no other patents with identical claims but multiple overlapping patents on similar APIs. The scope appears sufficiently distinct to provide exclusivity.
Litigation and market exclusivity considerations
Currently, no litigations or oppositions target HUE033011 in Hungary or regional jurisdictions. The claims' specificity reduces infringement ambiguities. Market exclusivity hinges on the patent’s enforceability and the absence of alternative patents covering generic versions.
Summary of patent landscape
- The patent covers a specific API, manufacturing process, and therapeutic use.
- It has moderate breadth, focusing on particular chemical structures.
- No significant prior art or invalidation threats are evident domestically.
- The patent family indicates strong commercial positioning in Europe.
Key takeaways
- HUE033011 provides a solid patent position in Hungary, with a lifecycle extending into the late 2030s.
- The claims are precisely targeted, limiting challenge risks but also potentially affecting generic entry.
- The patent landscape suggests limited competition within the same chemical space but proximity to other similar patents.
- Strategic patent family filings in other key markets reinforce the position.
FAQs
Q1: Can the scope of the claims be challenged?
Yes. Competitors may challenge based on prior art if they can demonstrate identical or substantially similar compounds or methods that predate the patent.
Q2: What is the patent term expiration date?
Typically 20 years from the earliest filing date; for HUE033011, it extends to around 2038, considering possible patent term extensions.
Q3: Are the claims limited to certain therapeutic indications?
Yes. The claims specify particular diseases or conditions, affecting the scope of patent protection for off-label uses.
Q4: Is this patent enforceable across Europe?
Yes. Given that it is part of an international patent family with filings in multiple jurisdictions, its enforceability depends on local patent regulations.
Q5: Could ongoing patent challenges affect this patent?
Possible. Future opposition or invalidation procedures could weaken the patent’s enforceability, especially if prior art discoveries emerge.
References
[1] European Patent Office. (2023). Patent database search. Retrieved from https://espacenet.com
[2] World Intellectual Property Organization. (2023). Patent landscape reports.
[3] U.S. Patent and Trademark Office. (2022). Patent documents.
